195
Participants
Start Date
November 17, 2022
Primary Completion Date
August 20, 2024
Study Completion Date
August 20, 2024
Triptorelin pamoate (embonate) salt
Triptorelin pamoate 22.5 mg (6-month formulation), i.m. injection, single dose on Day 1.
Affiliated Hospital of Hebei University, Baoding
Beijing Hospital, Beijing
Peking University First Hospital, Beijing
Peking University People's Hospital, Beijing
Hunan Cancer Hospital, Changsha
West China Hospital of Sichuan University, Chengdu
Chongqing University Cancer Hospital, Chongqing
The First Affiliated Hospital of Chongqing Medical University, Chongqing
Deyang People's Hospital, Deyang
Sun Yat-Sen University Cancer Center, Guangzhou
Guizhou Provincial People's Hospital, Guiyang
The Affiliated Hospital of Guizhou Medical University, Guiyang
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Qilu Hospital of Shandong University, Jinan
Shandong Provincial Hospital, Jinan
Nanjing Drum Tower Hospital, Nanjing
Zhongda Hospital Southeast University, Nanjing
Ningbo First Hospital, Ningbo
Fudan University Shang Hai Cancer Center, Shanghai
Shanghai Fifth People's Hospital, Shanghai
Shanghai Tongji Hospital, Shanghai
Liaoning Cancer Hospital & Institute, Shenyang
The First Hospital of China Medical University, Shenyang
Peking University Shenzhen Hospital, Shenzhen
Suining Central Hospital, Suining
The Second Affiliated Hospital of Soochow University, Suzhou
Tianjin Cancer Hospital, Tianjin
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
The First Affiliated Hospital of Wannan Medical College, Wuhu
The Second Affiliated Hospital of Wannan Medical College, Wuhu
Wuxi People's Hospital, Wuxi
Northern Jiangsu People's Hospital, Yangzhou
Subei People's Hospital, Yangzhou
Yantai Yuhuangding Hospital, Yantai
Henan Cancer Hospital, Zhengzhou
Zigong First People's Hospital, Zigong
Lead Sponsor
Ipsen
INDUSTRY